目的 探究痰熱清注射液聯(lián)合利奈唑胺治療老年肺炎的臨床療效。方法 選取2014年3月—2015年3月成都市公共衛(wèi)生臨床醫(yī)療中心收治的老年肺炎患者180例,隨機分為對照組和治療組,每組各90例。對照組靜脈滴注利奈唑胺注射液,600 mg/次,2次/d。治療組在對照組治療基礎(chǔ)上給予痰熱清注射液20 mL/次,加入到250 mL生理鹽水中靜脈滴注,1次/d。兩組均連續(xù)治療14 d。觀察兩組的臨床療效,同時比較兩組功能獨立性評定(FIM)評分、超敏C-反應(yīng)蛋白(hs-CRP)、白細胞、中性粒細胞、血小板、尿氮素水平變化情況。結(jié)果 治療后,對照組和治療組的總有效率分別為76.67%、93.33%,兩組比較差異有統(tǒng)計學意義(P <0.05)。治療后,兩組重度依賴度患者均有明顯的減少(P <0.05),輕度依賴患者均顯著增多(P <0.05);治療組治療后重度依賴患者明顯少于對照組,輕度依賴患者明顯多于對照組,兩組比較差異具有統(tǒng)計學意義(P <0.05)。治療后,兩組患者hs-CRP、白細胞和中性粒細胞均較治療前顯著降低,同組治療前后差異有統(tǒng)計學意義(P <0.05);且治療組的下降程度優(yōu)于對照組,兩組比較差異有統(tǒng)計學意義(P <0.05)。結(jié)論 痰熱清注射液聯(lián)合利奈唑胺治療老年肺炎具有較好的臨床療效,可降低患者hs-CRP、白細胞和中性粒細胞計數(shù),且不良反應(yīng)發(fā)生率低,具有一定的臨床推廣應(yīng)用價值。

Objective To observe the clinical effect of Tanreqing Injection combined with linezolid in treatment of elderly pneumonia. Methods Patients (180 cases) with elderly pneumonia in Public Health Clinical Center of Chengdu from March 2014 to March 2015 were randomly divided into control and treatment groups, and each group had 90 cases. The patients in the control group were iv administered with Linezolid Injection, 600 mg/time, twice daily. The patients in the treatment group were iv administered with Tanreqing Injection on the basis of control group, 20 mL/time adding into 250 mL physiological saline, once daily. Two groups were treated for 14 d. After treatment, the efficacy was evaluated, the changes of functional independence evaluation (FIM) scores, hs-CRP, white blood cells, neutrophils, platelets and urine nitrogen in two groups were compared. Results After treatment, the efficacies in the control and treatment groups were 76.67% and 93.33%, respectively, and there was difference between two groups (P < 0.05). After treatment, patients with severe dependence in two groups had significant reduction (P < 0.05), while mild dependence patients were significantly increased (P < 0.05). The severe dependence patients in treatment group were less than that in the control group, and mild dependence patients were more than that in the control group, and there was difference between two groups (P <0.05). After treatment, hs-CRP, white blood cells and neutrophils in two groups were significantly reduced, and the difference was statistically significant in the same group (P < 0.05). And these indicators in treatment group improved better than those in the control group, with significant differences between two groups (P < 0.05). Conclusion Tanreqing Injection combined with linezolid has good clinical efficacy in treatment of elderly pneumonia, and can reduce hs-CRP, white blood cells and neutrophils with low incidence of adverse reactions, which has a certain clinical application value.